Celltrion

Celltrion, based in Incheon, South Korea, is a pharmaceutical company listed as KRX: 068270. Celltrion is a biopharmaceutical company that researches, develops, manufactures and markets biosimilars and novel therapeutics across immunology, oncology and ophthalmology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing CT-P51 and CT-P44(Daratumumab) in non-small-cell lung cancer and multiple myeloma. The largest, NCT06952478 (A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma), plans to enrol 486 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.